Skip to main content

C-Reactive Protein (CRP)

C-reactive protein is a hepatically synthesized positive acute-phase protein and pentraxin family member with a half-life of ~ 19 hours.[1] It is the prototypic acute-phase reactant, first discovered in 1930 in the sera of patients with pneumococcal pneumonia.[2] CRP is one of the most widely requested laboratory tests due to its extraordinary dynamic range — serum concentrations can increase 100- to 1000-fold within 6–72 hours of an inflammatory stimulus — and its exceptional preanalytical stability.[3][4][5]

For the reconstructive urologist and urogynecologist, CRP serves three distinct roles: (1) the etiologic anchor for interpreting low albumin / prealbumin (part of the GLIM etiologic criterion for malnutrition), (2) the workhorse marker for postoperative inflammation, infection, and complication surveillance, and (3) the preoperative cardiovascular-risk signal in older patients facing major elective reconstruction.

Biochemistry and Kinetics​

CRP is a pentameric protein composed of five identical subunits arranged in cyclic symmetry. It binds phosphocholine on microbial surfaces and damaged cell membranes, activating the classical complement pathway and enhancing phagocytosis.[6][7] Key kinetic features:

  • Synthesis is driven primarily by IL-6, with contributions from IL-1 and TNF.[3][5]
  • Hepatic synthesis begins 6–8 hours after stimulus; plasma levels start rising at 12–24 hours and peak at 36–50 hours.[1][8]
  • Half-life is ~ 19 hours, with hepatic clearance. Levels decline rapidly once the inflammatory stimulus resolves.[1][9]
  • In healthy individuals, median CRP is approximately 0.8 mg/L.[1][10]

Two Distinct Assays: Standard CRP vs hsCRP​

A critical distinction exists between the two CRP assays used in clinical practice:

  • Standard CRP — Detection limit ~ 3–10 mg/L. Used for monitoring acute inflammation, infection, sepsis, and autoimmune flares. Values 10–40 mg/L suggest mild inflammation; 40–200 mg/L suggest acute inflammation or bacterial infection.[10][11]
  • High-sensitivity CRP (hsCRP) — Detection limit ~ 0.3 mg/L. Designed to measure low-grade subclinical inflammation relevant to cardiovascular risk assessment. Risk categories: < 1 mg/L (low), 1–3 mg/L (average), > 3 mg/L (higher). Values > 10 mg/L likely reflect an acute-phase response and should be repeated in 2–3 weeks; use the lower value for risk prediction.[12][13]

Clinical Applications​

1. Postoperative Inflammation, Infection, and Complication Surveillance​

CRP is widely used for diagnosing and monitoring postoperative infection, though it cannot distinguish bacterial from viral etiology on its own.[14] The SCCM/IDSA guidelines note that CRP and procalcitonin (PCT) have similar diagnostic accuracy for sepsis (AUC ~ 0.85 for PCT, comparable for CRP); the literature does not strongly favor one over the other.[8] Unlike PCT, CRP concentrations can be affected by neutropenia, immunodeficiency, and NSAID use.[8]

Postoperative CRP kinetics follow a stereotyped pattern: a peak around postoperative day 3 with a ≥ 30-fold rise above baseline after major elective surgery (validated in hip arthroplasty by Battistelli 2014).[15] A persistently rising or non-resolving CRP beyond POD 3–4 is the canonical signal of complication — surgical-site infection, intra-abdominal collection, urine leak, anastomotic leak, or pelvic abscess. This kinetic envelope is the basis of CRP-guided enhanced-recovery dashboards in colorectal and pelvic surgery.

2. Relationship to Visceral Proteins (Albumin, Prealbumin, Transferrin)​

CRP is the key positive acute-phase protein whose rise mirrors the decline of negative acute-phase proteins. The ASPEN position paper and ACG guideline both recommend using CRP alongside prealbumin to differentiate inflammatory-driven declines from nutritional deficiency.[16][17] In a prospective study of 2,465 ED patients, elevated CRP was the strongest independent predictor of hypoalbuminemia (adjusted OR 10.51), far exceeding the contribution of nutritional risk (adjusted OR 2.87).[18] In elderly recuperative-care patients, inflammation markers (particularly CRP and IL-6) accounted for 56% of the variance in prealbumin change, while protein intake accounted for only 6%.[19]

3. Cardiovascular Risk Assessment​

The 2025 ACC Scientific Statement on Inflammation and Cardiovascular Disease now recommends universal screening of hsCRP in both primary and secondary CVD prevention, stating it represents "a major clinical opportunity":[20]

  • A meta-analysis of 54 studies (160,309 individuals) found a 1-SD increase in hsCRP was associated with a 37% increased risk of CHD and 55% increased risk of cardiovascular death — comparable in magnitude to systolic blood pressure.[20]
  • UK Biobank (n = 448,653) confirmed hsCRP > 3 mg/L was associated with 34% higher MACE, 61% higher CV death, and 54% higher all-cause death vs hsCRP < 1 mg/L.[21]
  • The JUPITER trial demonstrated rosuvastatin reduced first cardiovascular events by 47% in patients with LDL < 130 mg/dL but hsCRP > 2 mg/L.[20][12]

4. Other Clinical Uses​

CRP measurement is also valuable in monitoring disease activity in rheumatoid arthritis, IBD, lupus, and other autoimmune conditions; assessing postoperative complications; and prognosticating in malignancy and COVID-19.[3][11]

Interpretation Frame — Albumin × CRP​

AlbuminCRPLikely picture
LowHighInflammation-driven hypoproteinemia — treat underlying disease
LowNormalPure nutritional depletion — respond to nutrition support
NormalHighAcute inflammation, nutritional reserve preserved
NormalNormalNo nutritional or inflammatory concern

This is the core GLIM etiologic criterion logic: inflammation status modifies how a low visceral protein is interpreted and acted on.

Limitations​

  • Non-specific — CRP rises in any inflammatory, infectious, or tissue-damaging process and cannot identify the source or etiology.[11][14]
  • Hepatic dependence — Severe liver failure may impair CRP production, potentially underestimating inflammation.[1]
  • Confounders — Obesity, smoking, oral contraceptives, and hormone replacement therapy can elevate baseline CRP.[4][20]
  • Timing — The 12–24 hour lag before CRP rises means it may be falsely normal very early in an acute process; PCT rises earlier (~ 4–5 hours).[1][8]

CRP vs Procalcitonin​

FeatureCRPProcalcitonin (PCT)
SourceHepatocytes (IL-6 driven)Parafollicular thyroid cells, neuroendocrine
Onset of rise6–8 hr (detectable 12–24 hr)4–5 hr
Peak36–50 hr6–8 hr
Half-life~ 19 hr~ 24 hr
Specificity for bacterial infectionLow (rises in viral, autoimmune, trauma)Moderate (also rises in severe viral illness)
Affected by neutropenia / immunodeficiencyYesNo
Point-of-care testingAvailable (~ 3 min)Available (~ 1 hr)
Cardiovascular risk assessmentYes (hsCRP)No

Reconstructive Relevance​

  • Postoperative complication surveillance — After radical cystectomy + urinary diversion, complex prolapse repair, gender-affirming phalloplasty / vaginoplasty, posterior urethroplasty, or any free-flap reconstruction, CRP kinetics are the most useful single bedside marker for leak / abscess / SSI detection. A non-resolving or rising CRP beyond POD 3–4 should prompt cross-sectional imaging.
  • Free-flap monitoring — In chronic-wound and free-tissue-transfer cohorts, CRP-prealbumin trending differentiates inflammation-driven from nutrition-driven failures and helps time secondary procedures (Kim 2023). Repeated POD CRP-prealbumin assessment is the institutional pattern in many reconstructive microsurgery practices.
  • GLIM diagnosis of malnutrition — Required to apply the etiologic criterion (inflammation-associated vs starvation-associated malnutrition) when working up a patient for elective reconstruction.
  • Preoperative cardiovascular risk in elective major reconstruction — Older patients facing radical cystectomy, ileal-conduit / neobladder, or staged gender-affirming surgery benefit from hsCRP screening under the 2025 ACC guidance, particularly when intermediate Framingham/ASCVD risk creates uncertainty about statin initiation or intensification before the operative course.
  • Do not interpret CRP in isolation in patients on NSAIDs (which suppress it modestly) or in profound liver failure (which limits synthesis).

See Also​

References​

1. Lelubre C, Anselin S, Zouaoui Boudjeltia K, Biston P, Piagnerelli M. "Interpretation of C-Reactive Protein Concentrations in Critically Ill Patients." BioMed Research International. 2013;2013:124021. doi:10.1155/2013/124021

2. Kushner I. "C-Reactive Protein — My Perspective on Its First Half Century, 1930–1982." Frontiers in Immunology. 2023;14:1150103. doi:10.3389/fimmu.2023.1150103

3. Plebani M. "Why C-Reactive Protein Is One of the Most Requested Tests in Clinical Laboratories?" Clinical Chemistry and Laboratory Medicine. 2023;61(9):1540–1545. doi:10.1515/cclm-2023-0086

4. Orlandi M, Graziani F, D'Aiuto F. "Periodontal therapy and cardiovascular risk." Periodontology 2000. 2020;83(1):107–124. doi:10.1111/prd.12299

5. Rajab IM, Hart PC, Potempa LA. "How C-Reactive Protein Structural Isoforms With Distinctive Bioactivities Affect Disease Progression." Frontiers in Immunology. 2020;11:2126. doi:10.3389/fimmu.2020.02126

6. Olson ME, Hornick MG, Stefanski A, et al. "A Biofunctional Review of C-Reactive Protein (CRP) as a Mediator of Inflammatory and Immune Responses." Frontiers in Immunology. 2023;14:1264383. doi:10.3389/fimmu.2023.1264383

7. Zhou HH, Tang YL, Xu TH, Cheng B. "C-Reactive Protein: Structure, Function, Regulation, and Role in Clinical Diseases." Frontiers in Immunology. 2024;15:1425168. doi:10.3389/fimmu.2024.1425168

8. O'Grady NP, Alexander E, Alhazzani W, et al. "Society of Critical Care Medicine and the Infectious Diseases Society of America Guidelines for Evaluating New Fever in Adult Patients in the ICU." Critical Care Medicine. 2023;51(11):1570–1586. doi:10.1097/CCM.0000000000006022

9. Stanimirovic J, Radovanovic J, Banjac K, et al. "Role of C-Reactive Protein in Diabetic Inflammation." Mediators of Inflammation. 2022;2022:3706508. doi:10.1155/2022/3706508

10. Myers GL, Rifai N, Tracy RP, et al. "CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice." Circulation. 2004;110(25):e545–e549. doi:10.1161/01.CIR.0000148980.87579.5E

11. National Library of Medicine (MedlinePlus). "C-Reactive Protein (CRP) Test." Accessed 2026.

12. Ridker PM. "A Test in Context: High-Sensitivity C-Reactive Protein." Journal of the American College of Cardiology. 2016;67(6):712–723. doi:10.1016/j.jacc.2015.11.037

13. Ridker PM. "Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week." Journal of the American College of Cardiology. 2018;72(25):3320–3331. doi:10.1016/j.jacc.2018.06.082

14. Smedemark SA, Aabenhus R, Llor C, et al. "Biomarkers as Point-of-Care Tests to Guide Prescription of Antibiotics in People With Acute Respiratory Infections in Primary Care." Cochrane Database of Systematic Reviews. 2022;10:CD010130. doi:10.1002/14651858.CD010130.pub3

15. Battistelli S, Fortina M, Carta S, et al. "Serum C-Reactive Protein and Procalcitonin Kinetics in Patients Undergoing Elective Total Hip Arthroplasty." BioMed Research International. 2014;2014:565080. doi:10.1155/2014/565080

16. Evans DC, Corkins MR, Malone A, et al. "The Use of Visceral Proteins as Nutrition Markers: An ASPEN Position Paper." Nutrition in Clinical Practice. 2021;36(1):22–28. doi:10.1002/ncp.10588

17. McClave SA, DiBaise JK, Mullin GE, Martindale RG. "ACG Clinical Guideline: Nutrition Therapy in the Adult Hospitalized Patient." The American Journal of Gastroenterology. 2016;111(3):315–334. doi:10.1038/ajg.2016.28

18. Eckart A, Struja T, Kutz A, et al. "Relationship of Nutritional Status, Inflammation, and Serum Albumin Levels During Acute Illness: A Prospective Study." The American Journal of Medicine. 2020;133(6):713–722.e7. doi:10.1016/j.amjmed.2019.10.031

19. Dennis RA, Johnson LE, Roberson PK, et al. "Changes in Prealbumin, Nutrient Intake, and Systemic Inflammation in Elderly Recuperative Care Patients." Journal of the American Geriatrics Society. 2008;56(7):1270–1275. doi:10.1111/j.1532-5415.2008.01789.x

20. Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. "Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement." Journal of the American College of Cardiology. 2025. doi:10.1016/j.jacc.2025.08.047

21. Kurt B, Reugels M, Schneider KM, et al. "C-Reactive Protein and Cardiovascular Risk in the General Population." European Heart Journal. 2025;ehaf937. doi:10.1093/eurheartj/ehaf937